- Home
- BNR vs IOTR Comparison
BNR vs IOTR Comparison
Compare BNR & IOTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- IOTR
- Stock Information
- Founded
- BNR 2014
- IOTR 2019
- Country
- BNR China
- IOTR Singapore
- Employees
- BNR N/A
- IOTR N/A
- Industry
- BNR Medical Specialities
- IOTR
- Sector
- BNR Health Care
- IOTR
- Exchange
- BNR Nasdaq
- IOTR NYSE
- Market Cap
- BNR 29.1M
- IOTR 29.5M
- IPO Year
- BNR 2020
- IOTR 2025
- Fundamental
- Price
- BNR $4.22
- IOTR $0.45
- Analyst Decision
- BNR
- IOTR
- Analyst Count
- BNR 0
- IOTR 0
- Target Price
- BNR N/A
- IOTR N/A
- AVG Volume (30 Days)
- BNR 29.7K
- IOTR 320.8K
- Earning Date
- BNR 08-21-2025
- IOTR 01-01-0001
- Dividend Yield
- BNR N/A
- IOTR N/A
- EPS Growth
- BNR N/A
- IOTR N/A
- EPS
- BNR N/A
- IOTR N/A
- Revenue
- BNR $72,112,038.00
- IOTR $10,478,550.00
- Revenue This Year
- BNR $136.32
- IOTR N/A
- Revenue Next Year
- BNR N/A
- IOTR N/A
- P/E Ratio
- BNR N/A
- IOTR N/A
- Revenue Growth
- BNR 0.53
- IOTR 22.27
- 52 Week Low
- BNR $2.18
- IOTR $0.31
- 52 Week High
- BNR $7.90
- IOTR $5.98
- Technical
- Relative Strength Index (RSI)
- BNR 63.77
- IOTR N/A
- Support Level
- BNR $3.06
- IOTR N/A
- Resistance Level
- BNR $3.50
- IOTR N/A
- Average True Range (ATR)
- BNR 0.21
- IOTR 0.00
- MACD
- BNR 0.05
- IOTR 0.00
- Stochastic Oscillator
- BNR 95.65
- IOTR 0.00
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.